Technology | Leads Implantable Devices | May 09, 2017

Biotronik Receives FDA Approval for Sentus ProMRI Quadripolar Left Ventricular Lead

Quadripolar lead with MR conditional CRT-D ensures heart failure patients have access to MRI scans

Biotronik Receives FDA Approval for Sentus ProMRI Quadripolar Left Ventricular Lead

May 9, 2017 — Biotronik announced U.S. Food and Drug Administration (FDA) approval and the launch of Sentus ProMRI, the thinnest quadripolar left ventricular lead available in the United States. This introduction completes Biotronik's second-generation ProMRI lead portfolio, which also includes Solia ProMRI and Plexa ProMRI.

Sentus ProMRI is approved for use with heart failure devices based on data collected during the QP ExCELs study. The study, which included 53 sites in the United States, demonstrated Sentus ProMRI QP's performance. Key data points included:

  • Complication-free rate of 97.1 percent at six months;
  • Lead dislodgement rate of 1.43 percent; and
  • Achievement of permanent pacing vector pacing threshold lower than 2.5 V for 93.4 percent of subjects at three months.

Sentus ProMRI is a quadripolar coronary sinus left ventricular (LV) lead with an isodiametric design that marries co-radial wire insulation technology and polyurethane coating for maximum flexibility and reduced friction. The lead's four electrodes feature Biotronik’s fractal iridium coating to maximize performance.

"With the array of leads available today, every patient should be implanted with an MR conditional device," said Venkat R. Iyer, M.D., electrophysiologist at Bayview Physicians Group in Norfolk, Va. "Our patients deserve nothing less than the best possible care. With MR [magnetic resonance] conditional solutions, we can help ensure this continues throughout the patient care journey."

Sentus ProMRI completes the ProMRI quadripolar system when used with Biotronik's Inventra HF-T QP cardiac resynchronization therapy defibrillator (CRT-D). This makes it the only MR conditional heart failure solution available in the United States that delivers ultra-high energy (42J) therapy on the first and every shock, according to the company. This system offers Closed Loop Stimulation (CLS) — Biotronik’s physiologic rate-adaptive algorithm that automatically optimizes to each patient's needs based on real-time metabolic demand. It also features Biotronik Home Monitoring, which has shown a 50 percent reduction in mortality1 in patients with heart failure, as proven in the IN-TIME study.

For more information: www.biotronik.com

 

Reference
1. Hindricks G, et al. The Lancet. 2014, 384 (9943).

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
Subscribe Now